{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:55Z","timestamp":1789584895366,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Erasmus MC grant","award":["2017"],"award-info":[{"award-number":["2017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The aim of this study was to increase somatostatin type-2 receptor (SSTR2) expression on neuroendocrine tumor (NET) cells using histone deacetylase inhibitors (HDACis), potentially increasing the uptake of SSTR2-targeted radiopharmaceuticals and subsequently improving treatment efficacy of peptide receptor radionuclide therapy (PRRT). Human NET cell lines BON-1, NCI-H727, and GOT1 were treated with HDACis (i.e., CI-994, entinostat, LMK-235, mocetinostat, panobinostat, or valproic acid (VPA); entinostat and VPA were the HDACis tested in GOT1 cells) to examine SSTR2 mRNA expression levels and uptake of SSTR2-targeting radiotracer [111In]In-DOTATATE. Reversibility of the induced effects was examined after drug-withdrawal. Finally, the effect of VPA on radiosensitivity was investigated. A strong stimulatory effect in BON-1, NCI-H727, and GOT1 cells was observed after HDACi treatment, both on SSTR2 mRNA expression levels and [111In]In-DOTATATE uptake. The effects of the HDACis were largely reversible over a period of seven days, demonstrating largest reductions within the first day. The reversibility profile of the induced effects suggests that proper timing of HDACi treatment is most likely essential for a beneficial outcome. In addition to increasing SSTR2 expression levels, VPA enhanced the radiosensitivity of all cell lines. In conclusion, HDACi treatment increased SSTR2 expression, and radiosensitivity was also enhanced upon VPA treatment.<\/jats:p>","DOI":"10.3390\/cancers13194905","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:03:42Z","timestamp":1632960222000},"page":"4905","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [111In]In-DOTATATE Uptake in NET Cells"],"prefix":"10.3390","volume":"13","author":[{"given":"Maria J.","family":"Klomp","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone U.","family":"Dalm","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"van Koetsveld","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1503\/cmaj.160771","article-title":"Principles of diagnosis and management of neuroendocrine tumours","volume":"189","author":"Raphael","year":"2017","journal-title":"Can. Med. Assoc. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1002\/cncr.28341","article-title":"Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes","volume":"119","author":"Okuwaki","year":"2013","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.humpath.2017.02.009","article-title":"Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome","volume":"65","author":"Klieser","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41588-018-0138-4","article-title":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","volume":"50","author":"Alvarez","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"R315","DOI":"10.1530\/ERC-17-0012","article-title":"Genetic and epigenetic drivers of neuroendocrine tumours (NET)","volume":"24","author":"Wiedmer","year":"2017","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11154-020-09607-z","article-title":"Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer","volume":"22","author":"Klomp","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13223-018-0259-4","article-title":"Histone modifications and their role in epigenetics of atopy and allergic diseases","volume":"14","author":"Alhamwe","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1369\/0022155413506582","article-title":"Histone deacetylases: A saga of perturbed acetylation homeostasis in cancer","volume":"62","author":"Parbin","year":"2014","journal-title":"J. Histochem. Cytochem."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hadden, M.J., and Advani, A. (2018). Histone Deacetylase Inhibitors and Diabetic Kidney Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092630"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gutjnl-2016-312539","article-title":"Epigenetic treatment of pancreatic cancer: Is there a therapeutic perspective on the horizon?","volume":"66","author":"Hessmann","year":"2016","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/jm301254q","article-title":"Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells","volume":"56","author":"Marek","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.18632\/oncotarget.9462","article-title":"Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells","volume":"9","author":"Veenstra","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.apradiso.2013.10.023","article-title":"Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs","volume":"85","author":"Chan","year":"2014","journal-title":"Appl. Radiat. Isot."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2967\/jnumed.115.167007","article-title":"Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models","volume":"57","author":"Dalm","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2967\/jnumed.118.224048","article-title":"Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro","volume":"60","author":"Jin","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2967\/jnumed.115.165092","article-title":"Upregulation of Key Molecules for Targeted Imaging and Therapy","volume":"57","author":"Taelman","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wanek, J., Gaisberger, M., Beyreis, M., Mayr, C., Helm, K., Primavesi, F., J\u00e4ger, T., Di Fazio, P., Jakab, M., and Wagner, A. (2018). Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103128"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.surg.2019.05.092","article-title":"Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment","volume":"167","author":"Guenter","year":"2020","journal-title":"Surgery"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Guenter, R.E., Aweda, T., Matos, D.M.C., Whitt, J., Chang, A.W., Cheng, E.Y., Liu, X.M., Chen, H., Lapi, S.E., and Jaskula-Sztul, R. (2019). Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors. Cancers, 11.","DOI":"10.3390\/cancers11060767"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1210\/en.2007-1525","article-title":"Identification of an Upstream Promoter of the Human Somatostatin Receptor, hSSTR2, Which Is Controlled by Epigenetic Modifications","volume":"149","author":"Torrisani","year":"2008","journal-title":"Endocrinology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000441849","article-title":"Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells","volume":"103","author":"Arvidsson","year":"2015","journal-title":"Neuroendocrinology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/1061186X.2015.1066794","article-title":"Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide\u2013drug conjugate via activating somatostatin receptor type II","volume":"24","author":"Sun","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-008-0944-5","article-title":"Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET\/CT","volume":"36","author":"Miederer","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yu, J., Cao, F., Zhao, X., Xie, Q., Lu, M., Li, J., Yang, Z., and Sun, Y. (2021). Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography\/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. Neuroendocrinology.","DOI":"10.1159\/000517530"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fendo.2018.00146","article-title":"Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines","volume":"9","author":"Exner","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3892\/ijmm_00000309","article-title":"Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation","volume":"25","author":"Kubota","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01025-5","article-title":"FK228 sensitizes radioresistant small cell lung cancer cells to radiation","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cbr.2009.0629","article-title":"HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells","volume":"24","author":"Chen","year":"2009","journal-title":"Cancer Biotherapy Radiopharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shah, R.G., Merlin, M.A., Adant, S., Zine-Eddine, F., Beauregard, J.-M., and Shah, G.M. (2021). Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers, 13.","DOI":"10.3390\/cancers13020232"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pros.23124","article-title":"Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer","volume":"76","author":"DiPippo","year":"2016","journal-title":"Prostate"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"Wei","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04107-w","article-title":"Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer","volume":"9","author":"McDevitt","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4905\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:07:35Z","timestamp":1760166455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":40,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194905"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194905","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}